Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Platform
Precision protein engineering generates superior molecules

Products
3 product candidates in the clinic as a result of research innovations

Partners
Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)

People
Great people making excellence happen, every day!
Technology
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Recent News
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
BioSpace – Sutro Maximizes Synergy to Treat Cancer and Preserve Quality of Life
https://www.biospace.com/article/sutro-maximizes-synergy-to-treat-cancer-and-preserve-quality-of-life/ By: Heather McKenzie Published: Jan. 12, 2021 Sutro Biopharma wants to use its antibody-drug conjugates (ADCs) as “laser-guided weapons” against cancer cells...